Clinical trials: Multi-Drug Resistant Organism Colonization, open to volunteers
Multi-Drug Resistant Organism Colonization
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO).
- Trial name
- NCT06321536
- Testing
- Allogeneic Microbiota in Glycerol (9%) (AMG)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University